You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  • Technology appraisal guidance
  • Reference number: TA218
  • Published:  23 March 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Research recommendations
  2. Guidance into practice

Tools and resources

Tools and resources to help you put the guidance into practice.

Research recommendations

  • Research recommendations information

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top